Insulet unveils positive RADIANT trial clinical data for its Omnipod 5 at the 18th international conference on ATTD.

Insulet Corporation PODD announced favorable RADIANT trial clinical data for its Omnipod 5 at the 18th International Conference on Advanced Technologies and Treatments for Diabetes (“ATTD”).

Participants began with an average HbA1c level of 8.1%. After three months, people who used Omnipod 5 improved HbA1c by an ...

Individuals transitioning from multiple daily injections to the Omnipod 5 system experienced an average HbA1c reduction of ...

Corporation shared new Omnipod 5 clinical data from its RADIANT study. Results from this multinational randomized controlled ...

Insulet Corporation’s RADIANT study shows glycaemic improvements with Omnipod 5 automated insulin delivery system: Action, Massachusetts Friday, March 21, 2025, 18:00 Hrs [IST] ...

Data from a controlled trial indicates that patients who switched from daily insulin injections to its Omnipod 5 automated ...

A randomized study from Insulet of adults and children with Type 1 diabetes found that moving from multiple daily injections ...

The use of an automated insulin delivery (AID) system reduced A1c and hyperglycemia without increasing hypoglycemia in people ...